J Perinatol

. 2024 Mar 8.

 doi: 10.1038/s41372-024-01921-7. Online ahead of print. https://pubmed.ncbi.nlm.nih.gov/38459371/

Use of surfactant beyond respiratory distress syndrome, what is the evidence?

Riddhi K Desai ¹, Hilal Yildiz Atar ², Satyan Lakshminrusimha ³, Rita M Ryan ⁴

Affiliations expand

• PMID: 38459371
• DOI: 10.1038/s41372-024-01921-7

Abstract

Surfactant replacement therapy is currently approved by the United States Food and Drug Administration (FDA) for premature infants with respiratory distress syndrome (RDS) caused by surfactant deficiency due to immaturity. There is strong evidence that surfactant decreases mortality and air leak syndromes in premature infants with RDS. However, surfactant is also used “off-label” for respiratory failure beyond classic RDS. This review discusses current evidence for the use of off-label surfactant therapy for (1) term infants with lung disease such as meconium aspiration syndrome (MAS), pneumonia/sepsis, and congenital diaphragmatic hernia (2) premature infants after 72 h for acute respiratory failure, and (3) the use of surfactant lavage. At last, we briefly describe the use of surfactants for drug delivery and the current evidence on evaluating infants for surfactant deficiency.

© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.